Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06001749 · ClinicalTrials.gov registry record · Phase 2
Psilocybin in Cancer Pain Study
A Phase 2 study of Advanced Cancer and Opioid-Related Disorders, sponsored by Yvan Beaussant, MD, MSci.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06001749: Recruiting Phase 2 study of Advanced Cancer and Opioid-Related Disorders, sponsored by Yvan Beaussant, MD, MSci.
NCT06001749 is a Phase 2 study of Advanced Cancer and Opioid-Related Disorders that is actively recruiting participants, run by Yvan Beaussant, MD, MSci. The registered enrollment target is 15 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06001749, a Phase 2 study of Advanced Cancer and Opioid-Related Disorders, is actively recruiting participants, sponsored by Yvan Beaussant, MD, MSci.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
Primary Outcome
Feasibility of intervention is defined as at least 60% of recruited participants will complete treatment and all assessments.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06001749 shows while recruiting
NCT06001749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (94% lower).
The record links to 5 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06001749 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06001749 about?
NCT06001749 is a clinical study titled "Psilocybin in Cancer Pain Study". The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivat...
What is the current status of trial NCT06001749?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-09-23. Estimated completion is 2026-12-31.
What conditions does trial NCT06001749 study?
This clinical trial studies the following conditions: Advanced Cancer, Opioid-Related Disorders, Pain Management, Advanced Cancers, Pain Management and Care.
What interventions are being tested in trial NCT06001749?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06001749?
This trial is sponsored by Yvan Beaussant, MD, MSci, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06001749 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06001749's enrollment target sits among peer trials
15 116th of 122 higher than 6 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
-
Intrapleural Catheter Daily Versus Three Times a Week Drainage
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI